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Aluminum phosphide, which is known as rice tablet in Iran, is being used in an increasing number of
cases of self-poisoning, and such cases have a high mortality rate. This poisoning has become an
important problem in various developing countries. There is no speciﬁc antidote, and supportive care
usually fails to restore cardiac systolic function and to resolve the patient's severe hypotension. The main
mechanism of action of aluminum phosphide is believed to be an inhibition of cytochrome c oxidase in
mitochondria followed by a stoppage of cellular metabolism. Currently, scientiﬁc attention is exploring
modifying the functioning of mitochondria using various novel therapeutic agents. One such agent is
coenzyme Q10, which has an important role in the mitochondrial electron transport chain. It is hydro-
phobic in nature acting as an antioxidant with the ability to scavenge oxygen-derived free radicals. As a
result of these properties, coenzyme Q10 has a crucial role to play in reducing cellular oxidative stress.
Moreover, there is evidence suggesting that coenzyme Q10 is able to enhance cardiac systolic function in
heart failure patients. Based on the above, we propose that treating patients suffering from aluminum
phosphide poisoning with coenzyme Q10 may be able to mitigate mitochondrial dysfunction and
improve heart contractility. This novel therapeutic intervention enables this by removing oxygen-derived
free radicals from the mitochondria and modifying mitochondrial functioning. We believe that this
treatment has potential as an effective adjunct to supportive care in cases of aluminum phosphide
poisoning and should also help to alleviate tissue injury.
Copyright © 2015, Buddhist Compassion Relief Tzu Chi Foundation. Published by Elsevier Taiwan LLC. All
rights reserved.1. Introduction
1.1. Aluminum phosphide poisoning
Aluminum phosphide, which is known as rice tablet in Iran, is
being used in an increasing number of cases of self-poisoning, and
these have a high mortality rate. Furthermore, self-poisoning using
aluminum phosphide is becoming an important problem in a
number of developing countries [1]. After ingestion, when the
aluminum phosphide comes in contact with the acidic contents of, Children's Medical Center,
edical Sciences, 62, Dr Gharib
asrabadi).
elief Tzu Chi Foundation. Publishethe stomach, phosphine gas (PH3) is released from the aluminum's
weak bonds and is then quickly absorbed through the gastric mu-
cosa [1,2]. The primary symptoms of aluminum phosphide
poisoning include retrosternal burning and vomiting, which are
followed by severe metabolic acidosis and cardiovascular incom-
petence [1]. Aluminum phosphide poisoning has a high mortality
rate because there is a major depression of cardiac functioning and,
consequently, the presence of refractory hypotension [3]. There is
no speciﬁc antidote to aluminum phosphide poisoning, and old-
fashioned gastrointestinal decontamination methods such as po-
tassium permanganate (1:10,000 solution) and activated charcoal
are not helpful. Medical toxicologists are only able to support the
functioning of the patient's vital organs; nevertheless, supportive
care usually fails to restore cardiac systolic function and to resolve
the patient's severe hypotension [3e6]. The main mechanism ofd by Elsevier Taiwan LLC. All rights reserved.
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believed to be an inhibition of cytochrome c oxidase in the mito-
chondria, which reduces ATP (adenosine triphosphate) production
and promotes oxidative stress [7,8].
Mitochondria are the main source of intracellular free radicals,
are able to transport electrons, and are involved in oxidative
phosphorylation as well as being part of the mechanisms that
control intracellular calcium homeostasis [9]. Singh et al [10]
demonstrated that aluminum phosphide causes a 45% reduction
in cytochrome c oxidase activity in humans. Dua and Gill [7]
demonstrated a 21e49% and 21e28% decrease in the activity of
complex I and complex II, respectively, using an animal model [7].
Furthermore, inhibition of the electron transport chainwill result in
overproduction by the mitochondria of reactive oxygen species.
Hence, in cases of aluminum phosphide poisoning, it would seem
that improving mitochondrial functioning and cellular bio-
energetics in general should be an effective way to combat the
multiorgan dysfunction associated with this deadly method of
poisoning.
1.2. Coenzyme Q10 shows speciﬁc characteristics
Coenzyme Q10 (CoQ10) is a biological antioxidant that is able to
induce depolarization of mitochondria and of the electron trans-
port chain that accepts electrons from complexes I and II and
transfers them to complex III [11]. It also is involved in adjusting
ATP production and decreasing free radical generation [12]. In an-
imal models, CoQ10 has been shown to have protective properties
against toxin-induced oxidative stress [13]. There is also evidence
that CoQ10 can play a role in increasing energy production at the
mitochondrial level to a degree that is sufﬁcient to bring about a
recovery in the contractility of the human myocardium [14].
We propose that CoQ10 might be useful as a potential cellular
defense against oxidative damage after aluminum phosphide
poisoning. We believe that in the presence of phosphine induced
cell toxicity, CoQ10 will be able to increase cytochrome c oxidase
activity; this, in turn, should help to restore mitochondrial activity
and ATP production, as well as improve systolic cardiac contrac-
tility. It is our belief that CoQ10 should be able to not only alleviate
oxidative stress at the level of the mitochondria and consequently
increase cell survival, but is also likely to help to resolve the mul-
tiorgan dysfunction present in patients with aluminum phosphide
poisoning.
2. Evaluation of this therapeutic option
Despite some recent uncertainty [3], most clinical toxicologists
believe that cytochrome c oxidase in mitochondria is the target for
phosphine's toxic effects [8,10]. This is supported by in vitro ex-
periments that have examined cytochrome c oxidase inhibition by
phosphine [7]. These studies suggest that, at the cellular level, the
reactivation of cytochrome c oxidase in the mitochondria might act
as an antidote in vivo in cases of aluminum phosphide and thus
enhance cell survival.
Coenzyme Q (2,3-dimethoxy-5-methyl-6-polyprenylbenzoqui
none) plays a key role in the mitochondrial respiratory chain.
CoQ10, the predominant form of CoQ in humans, consists of a polar
quinoid head group attached to 10 hydrophobic isoprenoid tail
units. The oxidized ubiquinone (UQ) form and the reduced ubiq-
uinol (UQH2) form are the foremost redox forms of CoQ [15]. Each
cell synthesizes CoQ itself, and themajor resources of CoQ10within
the body's tissues are found in the mitochondria of the myocytes
and myocardiocytes [16,17]. During an oxidative assault, UQH2 is
destroyed by an oxidation chain reaction that propagates by itself,
and ubisemiquinone radical generation becomes a self-perpetuating reaction. This means that when mitochondria are
exposed to oxidants such as phosphine, this will increase super-
oxide production as well as decrease the CoQ content of the
mitochondria [15].
Kwong et al [18] have reported that there is an increase in total
CoQ content across all tissue homogenates after CoQ supplemen-
tation. Moreover, concentrations of CoQ were found to be signiﬁ-
cantly higher in the mitochondria of various tissues, particularly in
myocytes and myocardiocytes. They also mentioned that, although
CoQ has antioxidant as well as oxidant properties, CoQ supple-
mentation does not seem to promote the mitochondrial generation
of oxidants but does seem to reduce oxidative stress by acting as an
antioxidant rather than a pro-oxidant. They then suggested that
these ﬁndings support the hypothesis that CoQ supplementation
may alleviate oxidative stress in certain organs [18]. Comparatively,
the protein carbonyl content in mitochondria is known to act as a
marker of oxidative damage to cellular proteins, and this measure
of oxidative damage is decreased when CoQ activity is active
scavenging radicals in mitochondria [18e21]. Following the
administration of CoQ10, there seems to be a general uptake by all
tissues. However, some speciﬁc organs show superior uptake, and a
higher concentration of CoQ10 is found in the mitochondria of
these tissues; in fact, the regulation of CoQ tissue contents is
autarchic [17,18].
As mentioned above, replacement of CoQ10 is able to effectively
reactivate the mitochondrial electron respiratory chain and alle-
viate oxidative stress. Furthermore, it has been demonstrated that
the employment of high doses of CoQ10 is safe and well tolerated
[22]. After the reactivation of mitochondrial ATP production, we
would expect an improvement in organ functioning. Interestingly,
several studies have conﬁrmed improvements in cardiac systolic
function among patients with heart failure after a short-term
treatment with CoQ10 and replenishment of the cardiac CoQ10
[23e26]. Another possible beneﬁt of CoQ10 replenishment might
be a restoration of the balance between energy demand and supply,
as well as a reduction in reactive oxygen production at the cellular
level, which in turn would ameliorate metabolic acidosis.
3. CoQ10 in clinical applications
CoQ10 is not approved by the Food and Drug Administration for
medical use and is traded in the marketplace as a dietary supple-
ment. The known adverse effects associated with CoQ10 intake are
gastrointestinal upset, headache, and skin rash [27]. As mentioned
above, it would seem that administration of a CoQ10 supplement
has a beneﬁcial effect on systolic function in heart failure patients.
However, a recent Cochrane Collaborationmeta-analysis found that
the available dataset is inconclusive, and there is no deﬁnite evi-
dence to conﬁrm its efﬁcacy [28]. In their study, Pringsheim et al
[29] concluded that there is good evidence to support the pre-
scription of CoQ10 as a prophylactic medication when treating
patients with migraine headaches. Other studies have indicated
that CoQ10 may beneﬁt patients with sperm abnormalities, statin-
induced myopathy, Huntington's disease, and Parkinson's disease;
these studies have not yet been supported by evidence from clinical
trials [30e33].
4. CoQ10 in evidence-based studies
Mortensen et al [34], in a randomized double-blind clinical trial,
evaluated the effect of CoQ10 on morbidity and mortality among
chronic heart failure patients. Their study showed that the long-
term treatment of these patients with CoQ10 was well tolerated
and that, in comparison to treatment with a placebo, there was a
decrease in cardiovascular mortality and a signiﬁcant improvement
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[34]. Pourmoghaddas et al [35] evaluated the effect of atorvastatin
alone and a combination of CoQ10 and atorvastatin as a standard
treatment for congestive heart failure. This study showed that after
4 months, treatment with a combination of atorvastatin and CoQ10
increased the patients' ejection fraction and improved their NYHA
functional class compared to the group of patients who were
treated with atorvastatin alone. Berman et al [36], in their double-
blind, placebo-controlled, randomized study, assessed the effect of
CoQ10 on patients with end-stage heart failure awaiting cardiac
transplantation. They concluded that the administration of CoQ10
to these heart transplant candidates for 3 months led to a signiﬁ-
cant improvement in their 6-minute walk test together with de-
creases in dyspnea, NYHA functional class, nocturia, and fatigue
compared to the placebo-treated patients [36].
5. Conclusion
In spite of advances in critical care and in clinical toxicologists'
efforts to eliminate symptoms of aluminum phosphide poisoning,
consumption of this chemical still results in high mortality. This
presents as increased rates of death from aluminum phosphide
poisoning in many developing countries. In such circumstances, a
novel treatment method for aluminum phosphide poisoning would
be very valuable indeed. The safety of CoQ10, its ability to revive
cellular energy production, the fact that it can act as a scavenger of
free radicals, and its ability to improve cardiac systolic functioning
are generally well accepted. Based on these ﬁndings, we suggest
that for patients who are suffering from aluminum phosphide
poisoning, CoQ10 is likely to act, at least to some extent, as an
antidote to the poison. We believe that treatment with CoQ10
might become an efﬁcient adjunct to supportive carewhen treating
cases of aluminum phosphide poisoning because it will help to
alleviate the tissue injury caused by the uptake of phosphine.
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